S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00

Miromatrix Medical Stock Forecast, Price & News

-0.27 (-2.89 %)
(As of 10/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
7,714 shs
Average Volume
42,770 shs
Market Capitalization
$182.05 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MIRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Miromatrix Medical and its competitors with MarketBeat's FREE daily newsletter.

About Miromatrix Medical

Miromatrix Medical Inc. engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company also develops organ-derived biological products for various applications, such as soft tissue reinforcement and wound care. It uses its perfusion decellularization/recellularization technology to engineer transplantable organs for the people who need them. Miromatrix Medical Inc. has strategical partnerships with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. Miromatrix Medical Inc. was formerly known as TayTech, Inc. The company was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$182.05 million
Next Earnings Date
Fiscal Year End
December 31
Not Optionable


Overall MarketRank

1.70 out of 5 stars

Medical Sector

886th out of 1,372 stocks

Biological Products, Except Diagnostic Industry

135th out of 197 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Miromatrix Medical (NASDAQ:MIRO) Frequently Asked Questions

Is Miromatrix Medical a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miromatrix Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Miromatrix Medical stock.
View analyst ratings for Miromatrix Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Miromatrix Medical?

Wall Street analysts have given Miromatrix Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Miromatrix Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Miromatrix Medical?

Miromatrix Medical saw a drop in short interest in the month of October. As of October 15th, there was short interest totaling 36,200 shares, a drop of 68.3% from the September 30th total of 114,100 shares. Based on an average daily trading volume, of 25,900 shares, the short-interest ratio is presently 1.4 days. Approximately 0.3% of the company's stock are short sold.
View Miromatrix Medical's Short Interest

What price target have analysts set for MIRO?

1 brokers have issued 1 year target prices for Miromatrix Medical's stock. Their forecasts range from $22.00 to $22.00. On average, they expect Miromatrix Medical's share price to reach $22.00 in the next year. This suggests a possible upside of 142.3% from the stock's current price.
View analysts' price targets for Miromatrix Medical
or view top-rated stocks among Wall Street analysts.

Who are Miromatrix Medical's key executives?

Miromatrix Medical's management team includes the following people:
  • Dr. Jeffrey James Ross Ph.D., CEO & Director (Age 45, Pay $323.49k)
  • Mr. Brian D. Niebur, Chief Financial Officer (Age 57, Pay $178.81k)

When did Miromatrix Medical IPO?

(MIRO) raised $32 million in an IPO on Thursday, June 24th 2021. The company issued 4,000,000 shares at $7.00-$9.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

What is Miromatrix Medical's stock symbol?

Miromatrix Medical trades on the NASDAQ under the ticker symbol "MIRO."

When does Miromatrix Medical's lock-up period expire?

Miromatrix Medical's lock-up period expires on Tuesday, December 21st. Miromatrix Medical had issued 4,800,000 shares in its initial public offering on June 24th. The total size of the offering was $43,200,000 based on an initial share price of $9.00. After the end of Miromatrix Medical's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Who are Miromatrix Medical's major shareholders?

Miromatrix Medical's stock is owned by many different retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (0.24%).

Which major investors are selling Miromatrix Medical stock?

MIRO stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc..

How do I buy shares of Miromatrix Medical?

Shares of MIRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Miromatrix Medical's stock price today?

One share of MIRO stock can currently be purchased for approximately $9.08.

How much money does Miromatrix Medical make?

Miromatrix Medical has a market capitalization of $182.05 million.

How many employees does Miromatrix Medical have?

Miromatrix Medical employs 37 workers across the globe.

What is Miromatrix Medical's official website?

The official website for Miromatrix Medical is www.miromatrix.com.

How can I contact Miromatrix Medical?

The company can be reached via phone at 952-942-6000 or via email at [email protected].

This page was last updated on 10/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.